Lupin (NSE:LUPIN, BOM:500257) has been assigned an ESG rating of 'Crisil ESG 69' by Crisil ESG Ratings & Analytics, according to a Friday Indian bourse filing.
The pharmaceutical company was also assigned a core ESG Rating of 'Crisil Core ESG 65' for fiscal year 2026, placing it in the 'Strong' category.